Latest heart op techniques, using AI & robots, discussed at docs' global meet
Tired of too many ads? go ad free now
The conference was a significant opportunity for doctors to share their latest findings and discuss cutting-edge technologies and advanced surgical techniques. The main objective was to find better ways to help patients with heart problems, making treatments more effective and less invasive.
Dr Deepak Puri, who leads the Cardiomersion organisation globally, gave two highly anticipated talks. In one, he introduced a new and improved way to perform chest surgeries called uniportal video-assisted thoracoscopic surgery (UVATS).
This technique allows doctors to perform complex operations through a tiny, single three-centimetre cut. Dr Puri explained that this new method is almost as clear to see as traditional open surgery, but it means much less pain, lower costs, and faster recovery for patients.
Another key speaker, Dr Johannes Bonatti, a heart surgeon from Pittsburgh, US, painted an exciting picture of the future. He described how robots are increasingly being used in heart surgery, not just for simpler procedures like bypasses, but also for more complex operations like replacing heart valves and even heart and lung transplants.
He discussed new surgical robots that are more flexible and offer better control, even enabling doctors to perform surgery remotely.
Following this vision, Dr Eric J Lehr, another minimally invasive heart surgeon from Seattle, US, discussed how robotics, along with artificial intelligence (AI), will revolutionise heart surgery. He showed how systems like the "da Vinci" robot have made procedures like heart valve repair and bypass surgery more precise and comfortable for patients.
Tired of too many ads? go ad free now
Dr Nidhi Puri, professor of anatomy from AIIMS Bilaspur, shared important insights about variations in a crucial blood vessel used in heart bypass surgery. Her presentation highlighted why it's so important for doctors to carefully check a patient's anatomy before surgery to avoid problems and achieve the best results.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
2 days ago
- First Post
Doctor explains: How diet, sleep and gut health impact GLP-1 and weight regulation
As GLP-1-based drugs like semaglutide gain popularity, new insights highlight how gut health, diet, protein, and sleep can naturally support GLP-1 hormone function. Firstpost presents expert views on how lifestyle changes can aid metabolic health and weight management. read more In recent years, GLP-1-based medications such as semaglutide and liraglutide have captured global attention for their remarkable effectiveness in treating type 2 diabetes and promoting weight loss. But beyond the pharmaceutical spotlight, growing research is now linking lifestyle factors such as gut health, protein intake and sleep quality to natural regulation of GLP-1 and other hormones that influence appetite and metabolism. To understand the science behind GLP-1, its connection to gut health and how diet and lifestyle can support its function, Firstpost spoke to Dr Pankaj Puri, Director, Gastroenterology, Fortis Escorts, Okhla (New Delhi) to shed light on the broader implications of this hormone and its role in modern metabolic health. STORY CONTINUES BELOW THIS AD What exactly is GLP-1, and why is it gaining attention in both medical research and mainstream conversations around weight management? Dr Puri: GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring hormone secreted by the L-cells in the small intestine in response to food intake. It plays a key role in regulating blood glucose levels by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying. Recently, GLP-1 receptor agonists such as semaglutide and liraglutide have garnered significant interest due to their effectiveness in promoting weight loss, improving blood sugar control in type 2 diabetes, and even showing promise in treating conditions like non-alcoholic fatty liver disease and liver fibrosis. These wide-ranging benefits have brought GLP-1 into the spotlight in both medical and mainstream circles. Beyond medications like semaglutide or liraglutide, how can everyday habits or dietary choices naturally support GLP-1 function in the body? Dr Puri: Several lifestyle choices can naturally boost GLP-1 levels. A balanced diet rich in protein, fibre, and unprocessed foods helps promote GLP-1 secretion. Regular exercise, quality sleep, and a healthy gut microbiome also play a role. On the other hand, ultra-processed foods and high-sugar diets may impair GLP-1 function and overall hormone balance. Nurturing gut health is key to enhancing GLP-1 activity. What is the connection between gut health and appetite regulation? Can fermented foods and prebiotics really influence hormone levels like GLP-1? Dr Puri: Absolutely. The gut-brain axis is central to appetite control, with hormones like GLP-1 playing a significant role in this communication. A healthy gut microbiome, supported by fibre-rich diets, fermented foods, and prebiotics promotes the release of beneficial hormones that regulate hunger and satiety. Fermented foods such as yogurt, kefir, and kimchi, along with prebiotics like garlic, onions and bananas help maintain gut diversity which in turn supports GLP-1 function. How important is protein in regulating satiety hormones, and what are the best sources to include in a daily diet? Dr Puri: Protein is one of the most satiating macronutrients. It triggers the release of satiety hormones such as GLP-1 and peptide YY, helping to curb appetite and reduce calorie intake. Consistently incorporating high-quality protein sources like eggs, lean meats (chicken, fish), dairy products (paneer, yogurt), legumes, and pulses into meals can help maintain appetite control and metabolic balance. Can you explain how soluble fibre impacts digestion and appetite hormones? How much fibre should one ideally consume each day? Dr Puri: Soluble fibre slows down gastric emptying and digestion, which prolongs feelings of fullness and stabilises blood sugar levels. It also nourishes the gut microbiome, indirectly enhancing GLP-1 activity. Good sources include oats, psyllium husk, chia seeds, and legumes. Ideally, adults should aim for at least 10–15 grams of soluble fibre daily as part of their overall dietary fibre intake (25–30 grams per day). What role do omega-3 fatty acids and healthy fats like olive oil or avocado play in insulin sensitivity and appetite control? Dr Puri: Omega-3 fatty acids, found in fatty fish (like salmon), walnuts, and flaxseeds, possess strong anti-inflammatory properties. By reducing systemic inflammation, they improve insulin sensitivity and metabolic function. Similarly, healthy fats such as those from olive oil and avocado help regulate satiety hormones and promote cardiovascular health, making them valuable components of a balanced diet. How does poor sleep affect appetite hormones and glucose metabolism, and what lifestyle practices can help restore hormonal balance? Dr Puri: Sleep deprivation disrupts key appetite-regulating hormones—namely increasing ghrelin (hunger hormone) and decreasing leptin (satiety hormone)—leading to increased cravings and risk of weight gain. Poor sleep also impairs glucose metabolism and insulin sensitivity. Restoring sleep hygiene, maintaining a consistent sleep schedule, and reducing screen time before bed can significantly help rebalance these hormones and support metabolic health. Some studies suggest that walking after meals can aid glucose regulation. Can you elaborate on how this simple habit affects metabolic and hormonal health? Dr Puri: Yes, walking after meals especially for 10–15 minutes can help reduce post-meal blood sugar spikes by promoting glucose uptake in muscles. It also improves insulin sensitivity and stimulates digestive processes. Incorporating this habit consistently can have a long-term positive impact on glucose control and weight management. How do irregular meal timings or skipping breakfast impact appetite-regulating hormones like GLP-1 and ghrelin? Dr Puri: Irregular meal patterns, including skipping breakfast, can disrupt the normal rhythm of hunger and satiety hormones. This often leads to increased ghrelin levels and reduced GLP-1 activity, triggering overeating later in the day. Adopting regular meal times and consuming a protein- and fibre-rich breakfast can help maintain hormonal balance and prevent excessive hunger throughout the day.
Time of India
2 days ago
- Time of India
From ouch to opportunity: India chases instant relief as pain market swells to Rs 16,000 crore; 5 brands pop up every week
India's pain relieving market is soaring, as more and more people are rushing to use over-the-counter (OTC) pills, sprays and creams to soothe everyday aches and pains. According to Nielsen data cited by industry executives, in the past five years, the segment has grown by more than a billion dollars, becoming the largest category within the non-prescription space. Since the onset of the pandemic, around five new pain relief brands have been launched each week on average, as per an ET report. In 2020, there were 1,552 brands catering to pain relief, including household names such as Volini, Omnigel, Dolo and Saridon. That figure has now soared to 2,771. Consumers are prioritising quick relief, said Shivam Puri, managing director at Cipla Health, 'Rise of urbanisation and increase in chronic illnesses have led to the need for faster, more convenient formats that are accessible across platforms,' Puri told ET. This rising demand comes despite continued warnings from healthcare professionals about the risks of indiscriminate painkiller use. Explosive growth The pain relief segment, particularly in urban markets, is largely driven by lifestyle factors such as gym injuries and sports-related strains. As a result, the combined market for analgesics and rubefacients has more than doubled, from Rs 6,820 crore in May 2020 to Rs 15,905 crore in May 2025, representing a compound annual growth rate (CAGR) of 18%. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Many Are Watching Tariffs - Few Are Watching What Nvidia Just Launched Seeking Alpha Read More Undo This is three times faster than the broader OTC market, which has grown at 6% CAGR to reach Rs 80,000 crore. Analgesics account for 75% of the pain management medication category. Paracetamol remains the dominant contributor, as per data from PharmaTrac, cited by ET. Sandeep Verma, who heads Bayer Pharmaceuticals' consumer health business for South Asia, noted a shift in perception since the Covid-19 outbreak. 'A lot of Indians view taking pain relief medication as a sign of weakness or worry about becoming dependent on it. Covid made many of us more aware of how stress, exhaustion, and even mild but recurring pain can chip away at our wellbeing and productivity,' he was quotde as saying. From chronic pain to lifestyle ailments Experts say that pain medications are being increasingly used to treat a wider range of issues, including inflammation and adjacent issues, leading to growing demand for pills. 'The analgesic segment that is dominated by paracetamols has been growing at a steady rate of 10%. This is because paracetamol medications are taken alongside other conditions that could include arthritis, any other bacterial or viral infection,' Sheetal Sapale, vice president, commercial, at PharmaTrac was quoted as saying. Nitin Kumar Sinha, consultant physician at WeCare Wellness in Mumbai, attributed the trend to rising lifestyle-related ailments. 'Lack of physical exercise, increase in body weight leading to knee and joint pain, anxiety, depression are all causes of increase in body pain, headaches or migraine,' he told ET. He also warned that self-medication is on the rise which can have serious consequences if used over a prolonged period of time, such as damage to the kidneys. IPCA's Zerodol SP, Janssen's Ultracet, GSK's Calpol, Micro Lab's Dolo, Torrent's Chymoral Forte and Cipla's Ibugesic Plus, are one of the top selling drugs. Most of these are prescription medications. Skin creams, allergies also see rise in OTC demand Pain relief isn't the only area where Indians are increasingly self-medicating. The demand for dermatological creams, traditionally prescribed by dermatologists, is also surging, particularly among Gen Z consumers. Bhanu Prakash, partner and healthcare services industry leader at Grant Thornton, said, 'Over-the-counter as a segment has grown post-Covid because of more knowledge and information for categories including anti-allergic medications, skin creams, tear drops among others.' Derma products, which are used to treat issues related to the skin and scalp, are now the second-largest non-prescription category after pain, expanding at a CAGR of 8% over the last five years, to become a Rs 14,854 crore market. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
2 days ago
- Time of India
Ooh, Aah, Ouch? Billion-$ Market Feels Your Pain
Mumbai: Indians are increasingly popping over-the-counter pills, using sprays or rubbing in creams to soothe their aches and pains, adding more than a billion dollars to the pain management market over the past five years. The category is the biggest within the non-prescription segment, and has seen about five brands launched every week on average since the pandemic, industry executives said, citing Nielsen data. There were 1,552 brands -including Volini, Omnigel, Dolo and Saridon -to tackle the twinges in 2020; now, there are 2,771. Consumers are more attentive to alleviating any pain on a more immediate basis, said Shivam Puri, managing director at Cipla Health, which sells the biggest rubefacient brand, Omnigel. Rubefacient are gels and creams for topical application. "Rise of urbanisation and increase in chronic illnesses have led to the need for faster, more convenient formats that are accessible across platforms," said Puri. This is despite medical professionals advising caution on random use of painkillers. The pain relief category is often lifestyle-driven in urban markets, especially with gym and sports injuries. As a result, the market for analgesics (pain relief medication) and rubefacient more than doubled to Rs 15,905 crore as of May this year, from Rs 6,820 crore as of May 2020, growing at a compounded annual rate of 18%. This is three times faster than overall over-the-counter market growth, which rose at 6% CAGR to Rs 80,000 crore. Analgesics account for 75% of the pain medication market and within analgesics, paracetamol is the biggest contributor, according to data from market researcher PharmaTrac. Covid has changed Indians' views on pain management, said Sandeep Verma, head for consumer health business for South Asia at Bayer Pharmaceuticals, which sells Saridon. "A lot of Indians view taking pain relief medication as a sign of weakness or worry about becoming dependent on it. Covid made many of us more aware of how stress, exhaustion, and even mild but recurring pain can chip away at our wellbeing and productivity," he said. "More people are starting to understand that living with untreated pain impacts their quality of life." Experts said pain management medications are also used to treat inflammation and adjacent issues, widening the need for the pills. "The analgesic segment that is dominated by paracetamols has been growing at a steady rate of 10%. This is because paracetamol medications are taken alongside other conditions that could include arthritis, any other bacterial or viral infection," said Sheetal Sapale, vice president, commercial, at PharmaTrac. Nitin Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said lifestyle-related problems - including rising stress levels, lack of sleep and increasing obesity - are reasons for increasing demand for pain medications.
